Abstract
Epithelial ovarian cancer (EOC) is the most commonly fatal gynecologic malignancy in developed countries. Most EOC patients are diagnosed at an advanced stage when disease has spread beyond the ovary. While many patients initially respond to surgery and chemotherapy, the long-term prognosis is generally unfavorable, with recurrence and development of drug-resistant disease. There is a critical need to identify new therapeutic agents that prolong disease-free intervals and effectively manage recurrent disease. Murine models of ovarian carcinoma are excellent models to study tumor biology in the search for new treatments for EOC. Described in this unit are methods for establishing xenograft or allograft models of EOC using ovarian carcinoma cell lines, in vivo imaging strategies for detection and quantification of EOC in transgenic and in xenograft/allograft models, and procedures for necropsy and pathological evaluation of experimental animals.
Original language | English |
---|---|
Pages (from-to) | 14.12.1-14.12.26 |
Journal | Current Protocols in Pharmacology |
Volume | Chapter 14 |
Issue number | SUPPL. 45 |
DOIs | |
State | Published - 2009 |
Keywords
- Bioluminescent imaging
- Epithelial ovarian cancer (EOC)
- In vivo imaging
- Magnetic resonance imaging
- Metastasis
- Orthotopic
- Transgenic mice
- Xenograft